Jazz Pharmaceuticals (JAZZ) Change in Acquisitions & Divestments (2012 - 2026)

Jazz Pharmaceuticals' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $520.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 67.74% year-over-year to $520.0 million in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 51.69% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 60.95% from the prior year.
• Change in Acquisitions & Divestments grew to $520.0 million in Q1 2026 per JAZZ's latest filing, from $180.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $520.0 million in Q1 2026 and bottomed at $20.0 million in Q3 2023.
• The 5-year median for Change in Acquisitions & Divestments is $270.0 million (2023), against an average of $254.6 million.
• Across the five-year window, Change in Acquisitions & Divestments soared 1675.0% in 2024 and slumped 37.93% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $60.0 million in 2022, then jumped by 316.67% to $250.0 million in 2023, then advanced by 16.0% to $290.0 million in 2024, then slumped by 37.93% to $180.0 million in 2025, then soared by 188.89% to $520.0 million in 2026.
• Per Business Quant, the three latest JAZZ Change in Acquisitions & Divestments figures stand at $520.0 million (Q1 2026), $180.0 million (Q4 2025), and $400.0 million (Q3 2025).